الصفحة الرئيسية>>Signaling Pathways>> Microbiology & Virology>> HIV>>Ritonavir-d6

Ritonavir-d6

رقم الكتالوجGC40221

Ritonavir-d6 is intended for use as an internal standard for the quantification of ritonavir by GC- or LC-MS.

Products are for research use only. Not for human use. We do not sell to patients.

Ritonavir-d6 التركيب الكيميائي

Cas No.: 1217720-20-1

الحجم السعر المخزون الكميّة
500μg
385٫00
متوفر
1mg
733٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ritonavir-d6 is intended for use as an internal standard for the quantification of ritonavir by GC- or LC-MS. Ritonavir is an HIV protease inhibitor. It inhibits recombinant HIV-1 protease by 79% when used at a concentration of 0.5 nM. It inhibits HIV-13B-induced cell death in MT-4 human T cell leukemia cells (EC50 = 25 nM) as well as cell death induced by HIV-1LAI, HIV-2ROD, and HIV-2EHO in human MT-2 cells (IC50s = 0.045, 0.13, and 0.24 μM, respectively). Ritonavir also inhibits the cytochrome P450 (CYP) isoform CYP3A (IC50 = 0.14 μM). It inhibits CYP-mediated oxidative metabolism of the HIV protease inhibitors saquinavir , indinavir , nelfinavir , and amprenavir in rat and human liver microsomes in a concentration-dependent manner. Ritonavir (10 mg/kg) also prevents decreases in plasma levels of these four compounds in rats. Formulations containing ritonavir have been used in the treatment of HIV-1 infection.

مراجعات

Review for Ritonavir-d6

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ritonavir-d6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.